ArticleNature communications2026
Analysis of isobaric quantitative proteomic data using TMT-Integrator and FragPipe computational platform.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cell painting and thermal proteome profiling for inference of drug targets and mechanism of action.Molecular systems biology · 2026Article
- A 15-layer multi-omics analysis of gastric cancer ecotypes provides therapeutic insights.Cell reports. Medicine · 2026Article
- Analysis of isobaric quantitative proteomic data using TMT-Integrator and FragPipe computational platform.Nature communications · 2026Article
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
Isobaric mass tags, such as isobaric tags for relative and absolute quantitation (iTRAQ) and tandem mass tag (TMT), are widely utilized for peptide and protein quantification in multiplex quantitative proteomics. We present TMT-Integrator, a bioinformatics tool for processing quantitation results from TMT and iTRAQ experiments, offering integrative reports at the gene, protein, peptide, and post-translational modification site levels. We demonstrate the versatility of TMT-Integrator using five publicly available TMT datasets: clear cell renal cell carcinoma (ccRCC) whole proteome and phosphoproteome datasets from the Clinical Proteomic Tumor Analysis Consortium, an E. coli dataset with 13 spike-in proteins, and two human cell lysate datasets showcasing the latest advances with the Thermo Orbitrap Astral mass spectrometer and TMTpro 35-plex reagents. Integrated into the widely used FragPipe computational platform ( https://fragpipe.nesvilab.org/ ), TMT-Integrator is a core component of TMT and iTRAQ data analysis workflows. We evaluated the performance of FragPipe coupled with TMT-Integrator analysis pipeline against MaxQuant and Proteome Discoverer with multiple benchmarks, facilitated by the bioinformatics tool OmicsEV. Our results show that FragPipe coupled with TMT-Integrator quantifies more proteins in the E. coli and ccRCC whole proteome datasets, quantifies more phosphorylated sites in the ccRCC phosphoproteome dataset, and overall delivers more robust quantification performance compared to other tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.